US 11,738,068 B2
Protein-containing aqueous liquid formulation
Hidehito Yasukawa, Kobe (JP); Takashi Hanada, Kobe (JP); Junya Tani, Kobe (JP); Shinji Okabe, Kobe (JP); and Yuuka Asano, Kobe (JP)
Assigned to JCR Pharmaceuticals Co., Ltd., Ashiya (JP)
Appl. No. 17/253,458
Filed by JCR Pharmaceuticals Co., Ltd., Ashiya (JP)
PCT Filed Jun. 25, 2019, PCT No. PCT/JP2019/025096
§ 371(c)(1), (2) Date Dec. 17, 2020,
PCT Pub. No. WO2020/004368, PCT Pub. Date Jan. 2, 2020.
Claims priority of application No. 2018-119494 (JP), filed on Jun. 25, 2018.
Prior Publication US 2021/0252112 A1, Aug. 19, 2021
Int. Cl. A61K 38/02 (2006.01); A61K 38/27 (2006.01); A61K 38/43 (2006.01); A61K 39/395 (2006.01); A61K 47/04 (2006.01); A61K 9/08 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); C07K 16/28 (2006.01)
CPC A61K 38/27 (2013.01) [A61K 38/43 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)] 4 Claims
 
1. An aqueous preparation, comprising
8 to 12 mM of a phosphate buffer; 4 to 8 mg/mL of growth hormone; 2 mg/mL of poloxamer 188; 3.3 mg/mL of phenol; and D-mannitol,
wherein the aqueous preparation has a pH of 6.2, an osmotic pressure ratio of 0.9 to 1.1, and does not include NaCl.